Pharma Journalist -

Gilead Sciences, Inc. announced the completion of the previously announced transaction to acquire Immunomedics, Inc. for approximately $21 billion in the aggregate. “We are very…
Read More...

We are only two weeks away from the much-anticipated 2nd Digital Exosome Based Therapeutic Development Summit (November 11-12). Bringing together industry leaders and newcomers in the…
Read More...

Avalon GloboCare Corp. and Adial Pharmaceuticals, Inc. announced formation of a strategic collaboration for global distribution of the Assure/Fastep COVID-19 IgG/IgM Rapid Test device…
Read More...

Catalent and BrainStorm Cell Therapeutics Inc announced an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of…
Read More...

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19…
Read More...

Extractables and Leachables USA Online is taking place October 26-28, 2020. The three day event includes sessions that are crucial to the extractables and leachables industry,…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD). An Orphan Drug Designation…
Read More...

Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, announced that it has entered into a research collaboration and…
Read More...

Gilead Sciences, Inc. announced 48-week data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy (bictegravir 50…
Read More...

ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. a clinical-stage, natural killer cell-based therapeutics company, announced that the first patient has been…
Read More...